Eton Pharmaceuticals, Inc.
ETON evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $1.65B
- Lead Asset:
- desmoda (Approved)
What it means
What to watch
Prepared research question
What matters most for ETON—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ETON
Eton Pharmaceuticals, Inc. (ETON) is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, with eleven commercial products and several late-stage candidates.
Key risk: Pipeline execution risk
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 3 clinical trials · 1 catalyst · 6 FDA decisions for Eton Pharmaceuticals, Inc..
Eton Pharmaceuticals, Inc. (ETON) is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, with eleven commercial products and several late-stage candidates.
- Eton has eleven commercial rare disease products including INCRELEX®, HEMANGEOL®, ALKINDI SPRINKLE®, KHINDIVI™, DESMODA™, GALZIN®, PKU GOLIKE®, IMPAVIDO®, Carglumic Acid, Betaine Anhydrous and Nitisinone [sec_mda · as of 2026-08-13].
- For Q2 2026, Eton reported record product sales of $37.6 million, representing 99% growth over Q2 2025 [news · published 2026-08-13].
- As of 2026-06-30, Eton had cash & equivalents of $26.8M, total revenue of $37.6M, net income of $11.6M, shareholders' equity of $46.6M, and total debt of $27.9M [sec].
- Eton has four additional product candidates in late-stage development: Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector [sec_mda · as of 2026-08-13].
- In July 2026, Eton entered into a license agreement for late-stage rare disease product candidate ASN-001 (timolol topical gel) from Auson Pharmaceuticals Inc. [sec · filed 2026-08-05].
What works
- Eton has a diversified portfolio of eleven commercial rare disease products, providing multiple revenue streams [sec_mda · as of 2026-08-13].
- The company achieved record revenue of $37.6 million in Q2 2026, a 99% increase over Q2 2025, indicating strong commercial execution [news · published 2026-08-13].
- Eton successfully relaunched HEMANGEOL® on May 1, 2026, with patient conversion completed ahead of schedule [news · published 2026-08-13].
- The company raised full-year 2026 revenue guidance to exceed $145 million, up from previous guidance of more than $120 million [news · published 2026-08-13].
What to weigh
- Eton's general and administrative expenses increased to $10,446 in Q1 2026 from $9,170 in Q1 2025, partly due to higher FDA fees as the company no longer qualifies for orphan drug fee waivers [sec_mda · as of 2026-05-14].
- The company's accumulated deficit is not disclosed in the provided chunks, but the company has total debt of $27.9M as of 2026-06-30 [sec].
- Eton's pipeline includes several late-stage candidates that require additional investment and regulatory approvals, with no guarantee of success [sec_mda · as of 2026-08-13].
- The company's financial performance is subject to substantial risks and uncertainties, as noted in its forward-looking statements [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Eton has eleven commercial rare disease products.
“The Company currently has eleven commercial rare disease products: INCRELEX®, HEMANGEOL®, ALKINDI SPRINKLE®, KHINDIVI™, DESMODA™, GALZIN®, PKU GOLIKE®, IMPAVIDO®, Carglumic Acid, Betaine Anhydrous and Nitisinone”
SEC MD&A · August 13, 2026
Q2 2026 product sales were $37.6 million, a 99% increase over Q2 2025.
“Record revenue, with Q2 2026 product sales of $37.6 million, representing 99% growth over Q2 2025”
News · August 13, 2026
Eton entered into a license agreement for ASN-001 in July 2026.
“On July 31, 2026, Eton Pharmaceuticals, Inc. ("Eton" or the "Company") entered into a license agreement (the "Agreement") for a late-stage rare disease product candidate ASN-001 (timolol topical gel) from Auson Pharmaceuticals Inc.”
SEC filings · August 5, 2026
Eton has four late-stage product candidates.
“The Company has four additional product candidates in late-stage development: Amglidia®, ET- 700, ET- 800 and ZENEO® hydrocortisone autoinjector.”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2044-04-03 · Patent_Expiry · DESMOPRESSIN ACETATE — Patent_Expiry: NDA219873 — Patent expiry for DESMOPRESSIN ACETATE could open the market to generic competition, potentially affecting Eton's revenue from related products.
Risks & what to watch (4)›
Key risks
- Pipeline execution risk — Late-stage candidates require regulatory approvals and additional investment; failure could impact growth [sec_mda · as of 2026-08-13].
- Debt and financial leverage — Total debt of $27.9M as of 2026-06-30 may increase financial risk if revenue growth slows [sec].
- Regulatory and FDA fee exposure — Higher FDA fees due to loss of orphan drug fee waivers increase operating costs [sec_mda · as of 2026-05-14].
- Patent expiry risk — Patent expiry for DESMOPRESSIN ACETATE (NDA219873) on 2044-04-03 could affect future revenue [catalyst].
What to watch
- Topline results from the ET-700 pilot clinical study for Wilson disease, expected in H2 2026 [news · published 2026-04-27].
- Completion of the bioavailability bridging study for ASN-001 and potential NDA submission [sec · filed 2026-08-05].
- Commercialization of IMPAVIDO® scheduled for September 2026 [sec_mda · as of 2026-08-13].
- Full-year 2026 revenue performance against the raised guidance of exceeding $145 million [news · published 2026-08-13].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run Eton Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Eton Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.49 · 19% dilution
Lead: Approved
4 candidates
1 upcoming, next in ~6382d
0 buys · 23 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 8.4%
- Days to cover
- 4.3
- Shares short
- 1,634,204
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ETON short interestGovernance
Frequently asked questions
What is the AI investment thesis for Eton Pharmaceuticals, Inc.?
Eton Pharmaceuticals, Inc. (ETON) is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, with eleven commercial products and several late-stage candidates.
What is Eton Pharmaceuticals, Inc.'s lead drug candidate?
Eton Pharmaceuticals, Inc.'s most advanced tracked candidate is desmoda (Approved).
What is Eton Pharmaceuticals, Inc.'s next catalyst?
Eton Pharmaceuticals, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA219873" — expected April 3, 2044.
Who is the CEO of Eton Pharmaceuticals, Inc.?
Mr. Sean E. Brynjelsen is the chief executive officer of Eton Pharmaceuticals, Inc. (ETON).
Where is Eton Pharmaceuticals, Inc. headquartered?
Eton Pharmaceuticals, Inc. (ETON) is headquartered in Deer Park, IL, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.